Replies to post #69525 on Biotech Values

[Preciouslife1]

How about: "HCV, Most likely to recoup intensive capital
expenditures during the rigorous, grueling FDA trial
process."

Which company will develop a new, novel, first in class
HCV and HBV treatment, which can also be a prophylaxis,
and maybe also a vaccine? Big $$$ at stake with almost
500 million having HCV alone, that THEY estimate.
Throw in HBV and the stakes are huge imho....

**PL1**